Abstract
Ischemic diseases including myocardial infarction (MI) and limb ischemia are some of the greatest causes of morbidity and mortality worldwide. Cell therapy is a potential treatment but is usually limited by poor survival and retention of donor cells injected at the target site. Since much of the therapeutic effects occur via cell-secreted paracrine factors, including extracellular vesicles (EVs), we developed a porous material for cell encapsulation which would improve donor cell retention and survival, while allowing EV secretion. Human donor cardiac mesenchymal cells were used as a model therapeutic cell and the encapsulation system could sustain three-dimensional cell growth and secretion of therapeutic factors. Secretion of EVs and protective growth factors were increased by encapsulation, and secreted EVs had hypoxia-protective, pro-angiogenic activities in in vitro assays. In a mouse model of limb ischemia the implant improved angiogenesis and blood flow, and in an MI model the system preserved ejection fraction %. In both instances, the encapsulation system greatly extended donor cell retention and survival compared to directly injected cells. This system represents a promising therapy for ischemic diseases and could be adapted for treatment of other diseases in the future.
| Original language | English |
|---|---|
| Pages (from-to) | 879-892 |
| Number of pages | 14 |
| Journal | Journal of Controlled Release |
| Volume | 352 |
| DOIs | |
| Publication status | Published - Dec 2022 |
Keywords
- Cardiac patch
- Cell encapsulation
- Cell therapy
- Exosome
- Extracellular vesicle
- Ischemic disease
- Limb ischemia
- Myocardial infarction
ASJC Scopus subject areas
- Pharmaceutical Science
Fingerprint
Dive into the research topics of 'Porous scaffold for mesenchymal cell encapsulation and exosome-based therapy of ischemic diseases'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS